Watson James Dean 4

What Happened
Director Watson James Dean was granted a derivative award on July 23, 2026: options covering 14,725 shares of Scribe Therapeutics (SCTX). The Form 4 reports an acquisition at $0.00 per share (i.e., no cash paid at grant). This is an award/option grant — not a purchase or sale of open‑market shares.

Key Details

• Transaction date: 2026-07-23; Form 4 filed: 2026-07-27 (filed 4 days after the transaction).
• Amount: 14,725 shares (derivative award) recorded at $0.00 per share.
• Shares owned after transaction: not disclosed in the provided filing excerpt.
• Footnote: Options vest in three equal installments — 1/3 on each of July 23, 2027; July 23, 2028; and July 23, 2029 — contingent on continued service.
• Transaction type/code: A (award/grant of derivative securities).

Context
This was a time-based option award with multi-year vesting; no shares were sold or exercised at grant. Such awards are common for directors and are not an immediate market signal (value is realized only as options vest and, if applicable, are exercised or sold). The filing appears to have been submitted several days after the reported grant date.